» Articles » PMID: 27080087

In Silico Methods for Drug Repurposing and Pharmacology

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Data in the biological, chemical, and clinical domains are accumulating at ever-increasing rates and have the potential to accelerate and inform drug development in new ways. Challenges and opportunities now lie in developing analytic tools to transform these often complex and heterogeneous data into testable hypotheses and actionable insights. This is the aim of computational pharmacology, which uses in silico techniques to better understand and predict how drugs affect biological systems, which can in turn improve clinical use, avoid unwanted side effects, and guide selection and development of better treatments. One exciting application of computational pharmacology is drug repurposing-finding new uses for existing drugs. Already yielding many promising candidates, this strategy has the potential to improve the efficiency of the drug development process and reach patient populations with previously unmet needs such as those with rare diseases. While current techniques in computational pharmacology and drug repurposing often focus on just a single data modality such as gene expression or drug-target interactions, we argue that methods such as matrix factorization that can integrate data within and across diverse data types have the potential to improve predictive performance and provide a fuller picture of a drug's pharmacological action. WIREs Syst Biol Med 2016, 8:186-210. doi: 10.1002/wsbm.1337 For further resources related to this article, please visit the WIREs website.

Citing Articles

Nanoparticles improved pheophorbide-a mediated photodynamic therapy for cancer.

Fakudze N, Abrahamse H, George B Lasers Med Sci. 2025; 40(1):78.

PMID: 39918741 PMC: 11805798. DOI: 10.1007/s10103-025-04320-2.


Comprehensive evaluation of pure and hybrid collaborative filtering in drug repurposing.

Reda C, Vie J, Wolkenhauer O Sci Rep. 2025; 15(1):2711.

PMID: 39837888 PMC: 11751339. DOI: 10.1038/s41598-025-85927-x.


Insilico discovery of novel Phosphodiesterase 4 (PDE4) inhibitors for the treatment of psoriasis: Insights from computer aided drug design approaches.

Alanzi A, Alsalhi M, Mothana R, Alqahtani J, Alqahtani M PLoS One. 2024; 19(11):e0305934.

PMID: 39535988 PMC: 11559988. DOI: 10.1371/journal.pone.0305934.


Identification of high-affinity Monoamine oxidase B inhibitors for depression and Parkinson's disease treatment: bioinformatic approach of drug repurposing.

Shahwan M, Prasad P, Yadav D, Altwaijry N, Khan M, Shamsi A Front Pharmacol. 2024; 15:1422080.

PMID: 39444620 PMC: 11496130. DOI: 10.3389/fphar.2024.1422080.


DrugReAlign: a multisource prompt framework for drug repurposing based on large language models.

Wei J, Zhuo L, Fu X, Zeng X, Wang L, Zou Q BMC Biol. 2024; 22(1):226.

PMID: 39379930 PMC: 11463036. DOI: 10.1186/s12915-024-02028-3.


References
1.
Chavali A, Blazier A, Tlaxca J, Jensen P, Pearson R, Papin J . Metabolic network analysis predicts efficacy of FDA-approved drugs targeting the causative agent of a neglected tropical disease. BMC Syst Biol. 2012; 6:27. PMC: 3388006. DOI: 10.1186/1752-0509-6-27. View

2.
White R, Tatonetti N, Shah N, Altman R, Horvitz E . Web-scale pharmacovigilance: listening to signals from the crowd. J Am Med Inform Assoc. 2013; 20(3):404-8. PMC: 3628066. DOI: 10.1136/amiajnl-2012-001482. View

3.
Ashburn T, Thor K . Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004; 3(8):673-83. DOI: 10.1038/nrd1468. View

4.
Arrowsmith J, Miller P . Trial watch: phase II and phase III attrition rates 2011-2012. Nat Rev Drug Discov. 2013; 12(8):569. DOI: 10.1038/nrd4090. View

5.
Emilsson V, Thorleifsson G, Zhang B, Leonardson A, Zink F, Zhu J . Genetics of gene expression and its effect on disease. Nature. 2008; 452(7186):423-8. DOI: 10.1038/nature06758. View